Cell and gene therapy

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

New DDW Highlights podcast: 7 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In significant news this week, the FDA in the US has removed red tape that… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

This week in drug discovery (30 June – 4 July) 

News round-up for 30 June – 4 July by DDW Senior Digital Content Editor Diana Turner. In significant news this week, the FDA in the US has removed red tape that limits which centres could give CAR-T therapy, in a move to improve access to the therapies. The… Read More

#News

Haemophilia
#Cell and gene therapy #Gene therapy #Haemophilia #University College London

Haemophilia gene therapy patients thriving a decade later

Patients who received a one-off gene therapy to treat haemophilia are still doing well up to 13 years later, finds a new study from researchers at University College London (UCL), the Royal Free Hospital and St Jude Children’s Research Hospital, Tennessee.  The study,… Read More

#Editor's Choice #News

Neurones in the brain
#Alzheimer's #Cell and gene therapy #Cognitive impairment #Gene therapy #Neurology #Neuroscience #University of California San Diego

Alzheimer’s gene therapy shows promise in preserving brain function

Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function. Unlike existing treatments for AD that target unhealthy protein deposits in the brain, the new approach could help address… Read More

#News

Circular DNA concept
#Cell and gene therapy #Circio Holding #circular RNAs #In vitro #In vivo

Circular RNA technology could open new therapeutic opportunities

Circular RNA technology continues to demonstrate broad capability to significantly boost protein expression level and durability for both viral and non-viral gene and cell therapy, according to new data.  Circio Holding shared the new and strengthened in vivo data for its circVec platform at the… Read More

#News

Gastrointestinal tract
#Cell and gene therapy #Cell therapy #CRISPR #Gastrointestinal #Gene editing #Oncology

CRISPR TIL therapy shows early success in GI cancers

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.   The results, published in Lancet Oncology, show encouraging signs of safety and potential… Read More

#Cancer Research #Editor's Choice #News

CAR-T cells attacking a cancer cell
#Cancer research #CAR-T #Cell and gene therapy #Leucid Bio #Solid tumours

First patient dosed in CAR-T therapy trial for solid tumours

Leucid Bio has dosed the first patient in the Phase I AERIAL trial evaluating the safety and clinical activity of LEU011 in patients with refractory solid tumours. Initiation of the AERIAL trial follows the successful first close of the Series A1 financing of £7.2 ($9.51) million in February 2025, co-led… Read More

#Cancer Research #News

Human adenovirus
#biological engineering #CAR-T #Cell and gene therapy #Cell therapy #EsoBiotec #In vivo

Revolutionising cancer treatment with viral vectors

CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer… Read More

#Cancer Research #Exclusive Content

#Artificial intelligence (AI) #CAR-T #Cell and gene therapy #Cell therapy

The future of cell therapy: AI has a role to play in breaking today’s barriers

Rafael Carazo Salas, CEO and Founder of CellVoyant, explores AI’s potential for cell therapies. AI is already making big strides in biotechnology and healthcare, from its remarkable accuracy in detecting breast cancer from mammograms, to AI platforms such as DeepMind’s AlphaFold revolutionising protein structure prediction. One of the most promising areas… Read More

#Exclusive Content

Biosafety testing
#Advanced Therapy Medicinal Products (ATMPs) #Bioluminescence #Biosafety testing #Cell and gene therapy #Microbiology #QA/QC

Enhancing rapid microbiology QC in cell & gene therapy

Dr Jeff Domsic, Product Manager Charles River Laboratories, discusses ATP-bioluminescence testing aligned with new regulatory guidelines. Over the past decade, the emergence of advanced therapy medicinal products (ATMPs) has fundamentally changed the approach to developing, manufacturing, administering, and treating diseases. These advanced modalities show significant promise and introduce various safety… Read More

#Exclusive Content #Opinion

#Advanced Therapies Europe #Bio Europe #Cell and gene therapy #Events

Industry insights from Spring 2025 events

Bio Europe Spring 2025 took place from 17-19 March in Milan, Italy, at the same time as Advanced Therapies London at the ExCel. Here, industry experts provided DDW’s Megan Thomas with insight from the events.   Bio Europe Spring Dr Carsten Rudolph, Cofounder and Chief Executive Officer at Ethris, said that… Read More

#Exclusive Content

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

New DDW Highlights podcast: 4 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a mixed bag of news for gene therapies this week, ranging from… Read More

#News

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

This week in drug discovery (24-28 February) 

News round-up for 23-28 February by DDW Senior Digital Content Editor Diana Spencer. It’s been a mixed bag of news for gene therapies this week, ranging from huge successes in treating sight impairment, cystic fibrosis and hearing loss, to the quick sale of a previously successful gene therapy… Read More

#News

#2025 predictions #Cell and gene therapy #Drug discovery

Cell and gene therapy: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience and cancer research. Here, looking at cell and gene therapy. For the last few years, the cell… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

Advanced therapies
#Advanced Therapies #Cell and gene therapy #Events #Opinion

Hot topics, news and discussions at Advanced Therapies Week 2025

Advanced Therapies Week (ATW) 2025 took place Dallas, US, from 20-23 January 2025. DDW’s Megan Thomas hears from industry experts in attendance and reports on news from the event.  Patient perspective Michalle Adkins, Director of Life Sciences Strategy and Direction at Emerson USA, said: “One of the most exciting things… Read More

#Business & Investment #Exclusive Content #Opinion

#Advanced Therapies #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

UK network to support innovation within advanced therapies

A new network aspires to create a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these treatments.   Cell and Gene Therapy Catapult (CGT Catapult) and the Birmingham Health Partners Centre for Regulatory Science and Innovation (CRSI)… Read More

#News